SCHEMBL407669

SCHEMBL407669

CN(Cc1ccccc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.73
LMNA P02545 2/20 0.73
KMT2A Q03164 5/20 0.65
MEN1 O00255 4/20 0.65
HTT P42858 3/20 0.65
ADRB2 P07550 1/20 0.65
MAPT P10636 1/20 0.65
CXCR4 P61073 2/20 0.63
NR1H3 Q13133 1/20 0.63
HPGD P15428 1/20 0.59
KDM4E B2RXH2 1/20 0.57
PKM P14618 1/20 0.57
MAPK1 P28482 1/20 0.57
TP53 P04637 1/20 0.57
HTR2C P28335 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9302981 0.89 NR1H3 (0.61) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL14470257 0.89 ALDH1A1 (0.69) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL14470114 0.88 KMT2A (0.70) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL9305267 0.88 NR1H3 (0.59) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL4072202 0.88 NR1H3 (0.63) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL11174358 0.88 NAMPT (0.62) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL10909120 0.88 ALDH1A1 (0.68) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL4236580 0.88 ALDH1A1 (0.68) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL9373823 0.86 ALDH1A1 (0.66) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL22265923 0.86 ALDH1A1 (0.66) ALDH1A1LMNAKMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106496167-A A kind of method that utilization thiazolinyl epoxide prepares r butenolides 合肥工业大学 2017-03-15 CN claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 US disclosed
CN-106496167-A A kind of method that utilization thiazolinyl epoxide prepares r butenolides 合肥工业大学 2017-03-15 CN disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 US disclosed
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20140155378-A9 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2014-06-05 US disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 US disclosed
WO-2007122173-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 US disclosed
US-7250444-B2 Pyrrole-based HMG-CoA reductase inhibitors PFIZER INC. (US) 2007-07-31 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20140155378-A9 c-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885LMNA 3308/4885KMT2A 769/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ADRA2C, ADRB2, CHRNA5 ALDH1A1 710/4885LMNA 2979/4885KMT2A 2135/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 ALDH1A1 2597/4885LMNA 3245/4885KMT2A 732/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 ALDH1A1 2578/4885LMNA 3308/4885KMT2A 769/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885LMNA 3308/4885KMT2A 769/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 ALDH1A1 2578/4885LMNA 3308/4885KMT2A 769/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET ALDH1A1 2072/4885LMNA 2924/4885KMT2A 977/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 ALDH1A1 2597/4885LMNA 3245/4885KMT2A 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.